A New Vein of Innovation: Can a Partnership Solve a $600M Problem?

BILLERICA, MA – June 23, 2026 – In the intricate world of healthcare, some of the most persistent challenges hide in plain sight, woven into the very fabric of routine patient care. One such challenge is the vascular access catheter, a ubiquitous and essential tool that, for decades, has been a source of costly and dangerous complications. Now, a new multi-year agreement between the medical device innovator Access Vascular, Inc. (AVI) and the supply chain giant Medline aims to fundamentally address this issue, posing a critical question to the $600 million catheter market: Is a new standard of care finally within reach?

The Decades-Old Complication

Every year, millions of peripherally inserted central catheters (PICCs) and midline catheters are placed in patients across the United States. These thin, flexible tubes are lifelines, delivering medications, hydration, and nutrition directly into the bloodstream. Yet, the very materials they are made from—typically polyurethane or silicone—have long been a double-edged sword. While structurally sound, these plastics are foreign bodies that can provoke a defensive response from the moment they are inserted.

The body’s reaction often involves the accumulation of proteins and platelets on the catheter’s surface, leading to the formation of blood clots (thrombosis) and blockages (occlusion). Research suggests that up to 30% of all patients with a vascular access device will experience a complication. These are not minor inconveniences. Catheter-related thrombosis can lead to serious morbidity, require device replacement, prolong hospital stays, and drive up healthcare costs significantly. For health systems already under immense financial pressure, these preventable complications represent a substantial and frustrating drain on resources.

For years, the industry has been anchored in these established polyurethane-based technologies, with innovation moving at a glacial pace. The problem wasn't a lack of awareness, but a lack of a truly disruptive solution that could be implemented at scale. This is the landscape that Access Vascular and Medline are now seeking to transform.

A Material Difference: The Promise of Hydrogel

The core of this new initiative lies in AVI’s proprietary biomaterial. Its HydroMID® and HydroPICC® catheters are not simply coated or treated; they are constructed from a unique hydrogel-based material designed to be inherently less reactive with the body. This hydrophilic material creates a barrier at the molecular level, effectively mimicking the body’s natural chemistry to repel the proteins and platelets that initiate clot formation. Pre-clinical data has been striking, with studies showing AVI's catheters can reduce thrombus accumulation by as much as 97% compared to standard polyurethane devices. Other research has pointed to a 99.998% reduction in bacterial adhesion, another critical factor in preventing catheter-related bloodstream infections.

This performance led the U.S. Food and Drug Administration to grant the devices a formal anti-thrombogenic indication in October 2025, a significant regulatory milestone. AVI’s catheters are now the only FDA-cleared PICCs and midlines on the market to carry this indication without relying on pharmaceutical coatings like heparin, thereby avoiding the potential for drug-related side effects.

“Vascular access has needed a better solution for decades – we built a technology that significantly reduces device-replacement and complication rates based on real-world evidence, now we’re bringing it to hospitals across the U.S. with Medline,” said James Biggins, Chief Executive Officer of Access Vascular. “This partnership gives us the commercial reach to match our clinical ambition.”

However, the FDA’s clearance came with a crucial note of scientific prudence: the anti-thrombogenic indication was based on laboratory studies, and its direct “clinical impact in human trials has not yet been evaluated.” This is the pivotal gap that the partnership must now bridge—translating promising lab results into proven, real-world patient outcomes.

The Power of the Pipeline: Medline's Strategic Play

Innovation, no matter how brilliant, is only as effective as its distribution. This is where Medline’s role becomes transformative. As one of the largest providers of medical-surgical products in the country, Medline possesses a supply chain and market presence that a specialized company like AVI could not build on its own. With a network that includes over 1,600 Prime Vendor customers—health systems where Medline is the primary supplier—the potential for rapid, widespread adoption is immense.

Medline’s strategy goes beyond simple distribution. The company will integrate the new catheters into its industry-leading customized kitting solutions. This means that hospitals will not just be buying a new catheter; they will receive fully assembled, procedure-ready kits tailored to their specific workflows. This seemingly small detail is critical for institutional innovation, as it lowers the barrier to adoption, ensures consistency in care, and improves clinical efficiency from day one.

“Advancing vascular access requires both innovation and the ability to deliver it reliably at scale,” noted Vish Bhave, executive vice president of Medline Brand. “This agreement allows us to pair clinically differentiated technology with our ability to deliver fully assembled, procedure-ready kits—helping health systems more seamlessly adopt solutions designed to address some of the most persistent challenges in vascular access.”

By combining AVI's advanced biomaterial with Medline's logistical prowess, the partnership represents a powerful model for how to amplify positive impact. It’s a symbiotic relationship where cutting-edge technology is married to the institutional infrastructure needed to make it a standard of care.

From the Lab to the Bedside

The co-branded catheters are expected to become available through Medline starting in late 2026. Until then, the focus will be on building the case for adoption. For clinicians on the front lines, the promise of a better tool is tantalizing. As Matthew Ostroff, a Vascular Access Coordinator at St. Joseph's Health, stated, “Innovations that address those challenges — particularly without relying on chemical additives — are worth paying attention to.” He added that solutions scaled through broad distribution “have the potential to set a new standard for performance and patient care, and that matters at the bedside every day.”

Success will hinge on demonstrating clear value to health systems. This means generating robust real-world evidence that proves the catheters not only improve patient outcomes but also reduce the total cost of care by minimizing complications and device replacements. Overcoming the market inertia of established giants like Becton Dickinson and Teleflex will require more than just a superior product; it will demand undeniable proof of its economic and clinical benefits. The collaboration between AVI’s clinical specialists and Medline’s 300-plus acute care representatives will be essential in communicating this value proposition to hospitals nationwide, turning a promising technology into a tangible improvement in our shared wellbeing.